The Great American Chip Reshoring
President Trump's proposal to impose tariffs of up to 300% on imported semiconductors aims to force a shift in global manufacturing. This creates a potential investment opportunity in U.S.-based semiconductor companies and their suppliers, who are positioned to gain from the drive to onshore production.
Your Basket's Financial Footprint
Analysis of basket market capitalisation and investor takeaways for The Great American Chip Reshoring.
- Large-cap dominance generally implies lower volatility and closer tracking of broad market moves, reducing idiosyncratic risk.
- Treat as a potential core holding for diversified portfolios rather than a speculative small‑cap growth play.
- Expect steady, long‑term appreciation rather than explosive short‑term gains; returns are likely more measured.
NVDA: $4.40T
AMD: $386.29B
INTC: $178.03B
- Other
About This Group of Stocks
Our Expert Thinking
President Trump's proposed tariffs of up to 300% on imported semiconductors could reshape the global technology landscape. This policy aims to incentivise a significant shift of manufacturing back to the United States, creating opportunities for domestic chip companies and their suppliers who stand to benefit from increased government investment and protected market share.
What You Need to Know
This group focuses on US-based semiconductor companies across the entire value chain - from chip designers and fabricators to equipment manufacturers and materials suppliers. These companies are positioned to capture growth as new fabrication plants are built domestically and supply chains are reshored to reduce dependence on foreign manufacturing.
Why These Stocks
These companies have been handpicked by professional analysts as key players in the domestic semiconductor ecosystem. They represent firms that could directly benefit from policy-driven reshoring initiatives, increased domestic production capacity, and the strategic push towards American semiconductor self-sufficiency.
Why You'll Want to Watch These Stocks
Manufacturing Renaissance
These companies could benefit from a massive shift in semiconductor production back to American soil. As new fabrication plants are built domestically, they're positioned to capture significant growth from this reshoring wave.
Policy Protection Advantage
With potential 300% tariffs on imported chips, these US-based companies could enjoy protected market share and reduced foreign competition. This policy shield creates a compelling investment backdrop for domestic semiconductor players.
Government Investment Boost
The push for semiconductor self-sufficiency means increased government funding and incentives for domestic chip production. These companies are well-positioned to benefit from this strategic national investment in American technology independence.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Aerospace Stocks: Could Airbus Issues Boost Boeing?
Airbus has cut its delivery targets after discovering a significant fuselage flaw in its A320 aircraft, causing production delays and requiring widespread inspections. This situation could create a significant opening for its main competitor, Boeing, and other aerospace manufacturers to capture market share from airlines seeking to avoid delivery uncertainties.
Cargo Capacity Crisis: Which Stocks May Benefit Most?
The crash of a UPS cargo plane has led to the grounding of an entire class of aging aircraft across the logistics industry. This creates a potential investment opportunity in competing cargo carriers and aircraft manufacturers poised to fill the resulting gap in shipping capacity.
UK-US Pharma Trade Deal | Tariff-Free Market Access
A new trade deal eliminates tariffs on pharmaceuticals between the UK and the US, strengthening transatlantic trade. This creates a powerful tailwind for pharmaceutical companies in both countries, potentially boosting exports, innovation, and profitability.